These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 28131192

  • 1. Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson's disease.
    Modreanu R, Cerquera SC, Martí MJ, Ríos J, Sánchez-Gómez A, Cámara A, Fernández M, Compta Y.
    J Neurol Sci; 2017 Feb 15; 373():223-229. PubMed ID: 28131192
    [Abstract] [Full Text] [Related]

  • 2. Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.
    Buongiorno M, Antonelli F, Compta Y, Fernandez Y, Pavia J, Lomeña F, Ríos J, Ramírez I, García JR, Soler M, Cámara A, Fernández M, Basora M, Salazar F, Sanchez-Etayo G, Valldeoriola F, Barrio JR, Marti MJ.
    J Alzheimers Dis; 2017 Feb 15; 55(3):1261-1272. PubMed ID: 27814297
    [Abstract] [Full Text] [Related]

  • 3. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.
    J Neurol Neurosurg Psychiatry; 2010 Oct 15; 81(10):1080-6. PubMed ID: 20547614
    [Abstract] [Full Text] [Related]

  • 4. Amyloid-β and τ biomarkers in Parkinson's disease-dementia.
    Buongiorno M, Compta Y, Martí MJ.
    J Neurol Sci; 2011 Nov 15; 310(1-2):25-30. PubMed ID: 21764078
    [Abstract] [Full Text] [Related]

  • 5. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.
    Parkinsonism Relat Disord; 2015 Jul 15; 21(7):758-64. PubMed ID: 25971633
    [Abstract] [Full Text] [Related]

  • 6. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
    Brockmann K, Schulte C, Deuschle C, Hauser AK, Heger T, Gasser T, Maetzler W, Berg D.
    Parkinsonism Relat Disord; 2015 Dec 15; 21(12):1427-34. PubMed ID: 26475624
    [Abstract] [Full Text] [Related]

  • 7. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
    Vranová HP, Hényková E, Kaiserová M, Menšíková K, Vaštík M, Mareš J, Hluštík P, Zapletalová J, Strnad M, Stejskal D, Kaňovský P.
    J Neurol Sci; 2014 Aug 15; 343(1-2):120-4. PubMed ID: 24928081
    [Abstract] [Full Text] [Related]

  • 8. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D.
    J Parkinsons Dis; 2015 Aug 15; 5(4):783-92. PubMed ID: 26599300
    [Abstract] [Full Text] [Related]

  • 9. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.
    Compta Y, Valente T, Saura J, Segura B, Iranzo Á, Serradell M, Junqué C, Tolosa E, Valldeoriola F, Muñoz E, Santamaria J, Cámara A, Fernández M, Fortea J, Buongiorno M, Molinuevo JL, Bargalló N, Martí MJ.
    J Neurol; 2015 Feb 15; 262(2):294-306. PubMed ID: 25380583
    [Abstract] [Full Text] [Related]

  • 10. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T, Zuo H, Ma D, Song D, Zhao Y, Cheng O.
    J Neuroinflammation; 2023 Jul 20; 20(1):167. PubMed ID: 37475029
    [Abstract] [Full Text] [Related]

  • 11. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.
    Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junqué C, Bargalló N, Tolosa E, Valldeoriola F, Muñoz E, Camara A, Buongiorno M, Martí MJ.
    Parkinsonism Relat Disord; 2012 Sep 20; 18(8):941-7. PubMed ID: 22595621
    [Abstract] [Full Text] [Related]

  • 12. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
    Wilson EN, Swarovski MS, Linortner P, Shahid M, Zuckerman AJ, Wang Q, Channappa D, Minhas PS, Mhatre SD, Plowey ED, Quinn JF, Zabetian CP, Tian L, Longo FM, Cholerton B, Montine TJ, Poston KL, Andreasson KI.
    Brain; 2020 Mar 01; 143(3):932-943. PubMed ID: 32065223
    [Abstract] [Full Text] [Related]

  • 13. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.
    Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P, Schindehuette J, Poser S, Wiltfang J, Otto M.
    Dement Geriatr Cogn Disord; 2006 Mar 01; 22(3):200-8. PubMed ID: 16899997
    [Abstract] [Full Text] [Related]

  • 14. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM, Parkinson's Progression Markers Initiative.
    JAMA Neurol; 2013 Oct 01; 70(10):1277-87. PubMed ID: 23979011
    [Abstract] [Full Text] [Related]

  • 15. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
    Bäckström DC, Eriksson Domellöf M, Linder J, Olsson B, Öhrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L.
    JAMA Neurol; 2015 Oct 01; 72(10):1175-82. PubMed ID: 26258692
    [Abstract] [Full Text] [Related]

  • 16. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C, Olivola E, Pierantozzi M, Cerroni R, Galati S, Saviozzi V, Mercuri NB, Stefani A.
    CNS Neurol Disord Drug Targets; 2017 Oct 01; 16(3):339-345. PubMed ID: 27934563
    [Abstract] [Full Text] [Related]

  • 17. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study.
    Compta Y, Pereira JB, Ríos J, Ibarretxe-Bilbao N, Junqué C, Bargalló N, Cámara A, Buongiorno M, Fernández M, Pont-Sunyer C, Martí MJ.
    Parkinsonism Relat Disord; 2013 Aug 01; 19(8):717-24. PubMed ID: 23643469
    [Abstract] [Full Text] [Related]

  • 18. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H, Någga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O.
    Arch Neurol; 2012 Nov 01; 69(11):1445-52. PubMed ID: 22925882
    [Abstract] [Full Text] [Related]

  • 19. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H, Tokuda T, El-Agnaf OMA, Ohmichi T, Miki A, Ohashi H, Owan Y, Saito Y, Yano S, Tsukie T, Ikeuchi T, Ono K.
    BMC Neurol; 2019 Jun 04; 19(1):113. PubMed ID: 31164098
    [Abstract] [Full Text] [Related]

  • 20. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.
    J Med Assoc Thai; 2011 Feb 04; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.